Universal Registration Document

Overview

The report describes ABIVAX's 2019 progress as a clinical-stage biotech focused on ABX464, including Phase 2b ulcerative-colitis development and a COVID-19 Phase 2b/3 trial, while ABX196 entered Phase 1/2 in hepatocellular carcinoma. Financially, R&D expenses were -€29.0 million and total operating revenue was €2,000 in 2019. At filing, the company reported 27 employees and an eight-member board with three women.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2019
Period: Ends 31 December 2019
Publication date: 25 May 2020
Language: English
Pages
File size

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services